Perioperative hyperglycemia is a risk factor for surgical site infections (SSI).
appropriate perioperative insulin therapy is required in patients with hyperglycemia. [3] [4] [5] [6] [7] Data regarding the impact of long-term glucose control on SSI have been conflicting in patients with diabetes mellitus (DM). In DM patients who underwent major non-cardiac surgery, a hemoglobin (Hb) A1c level of <7% was significantly associated with decreased infectious complications with an adjusted odds ratio (OR) of 2.13. 9 In contrast, Latham et al. 8 reported that DM and postoperative hyperglycemia were independently associated with the development of SSI. However, among DM patients, elevated Hb
Alc values were not associated with a statistically significantly increased risk of infection. Acott et al. 10 also described that there was no correlation between risk of complication and Hb A1c level.
These reports suggest that short-term perioperative glucose control may be more impactful in decreasing SSI than long-term control of Hb A1c.
Earlier guidelines for prevention of SSI from the Centers for Disease Prevention and Control (CDC) 3 published in 1999
recommended perioperative treatment of hyperglycemia (≥200 mg/ dL) in patients with DM. The Surgical Care Improvement Project 5 (SCIP) developed a quality performance measure to maintain the 6 a.m. controlled blood glucose level (BG) at <200 mg/dL in cardiac surgery (<180 mg/dL in the updated version 11 ). This recommendation has been challenged by recent studies suggesting that an even lower target BG is required to prevent SSI. [12] [13] [14] [15] [16] [17] [18] The intensive insulin administration protocol (intensive protocol), however, leads to an increased risk of hypoglycemia, which, in turn, is associated with increased morbidity and mortality. 19, 20 It seems that very strict glycemic control has modest benefits, with adverse effects often outweighing these advantages in critically ill patients. However, recent studies have indicated differing results for certain patient subgroups, such as surgical patients with acute operative hyperglycemia in the immediate postoperative period. [12] [13] [14] [15] [16] As patients with DM have a higher risk of cardiovascular disease, and the association with SSI was significantly higher for cardiac surgery compared with other surgeries in DM patients 21 (OR 2.03, 95%
confidence interval [CI] 1.13-4.05), many of the available studies evaluating the efficacy of glycemic control on SSI were limited to cardiac surgery patients, 22 which raised questions about the generalizability of the results to patients undergoing other surgical procedures. 12 Vigorous studies have been recently conducted to clarify the efficacy of tight (strict) glycemic control in patients undergoing gastroenterological surgery, and four of 15 randomized clinical trials (RCT) comparing intensive with conventional protocols were carried out in patients undergoing abdominal surgery (nine were conducted for cardiac surgery). 23 The definition of intensive protocol varies from 'moderately strict glycemic control' with an upper limit target of 150 mg/dL to 'very strict control' with a target of 110 mg/dL ( A post-hoc analysis of the NICE-SUGAR study database 20 showed that very strict control leads to moderate and severe hypoglycemia, both of which are associated with an increased risk of death, whereas high incidence of hypoglycemia possibly leads to increased mortality in patients assigned to a group under very strict control.
Therefore, it would be prudent to ensure that strategies for managing the BG in critically ill patients focus not only on the control of hyperglycemia but also on avoidance of hypoglycemia. The clustered ranking plot reported by Yamada et al. 28 provided precise risk estimates and better information about the hierarchy of target BG ranges for achieving safe and effective glycemic control in critically ill patients, and a BG of 140-180 mg/dL achieved the best outcome in relation to all-cause mortality and hypoglycemia. Surviving Sepsis Campaign guidelines 30 for the management of severe sepsis and septic shock recommended a protocolized approach with a target upper BG of 180 mg/dL rather than 110 mg/dL.
| Patients undergoing surgery
There are currently several debates regarding the benefits of strict glucose control in less critically ill patients undergoing elective surgery as opposed to critically ill (medical) patients [12] [13] [14] [15] [16] [17] [18] (Table 2) .
Although the recommended target BG is 140-180 mg/dL for most ICU patients, 27 a recent meta-analysis 23 comparing the efficacy between an intensive and a conventional protocol in patients undergoing surgery showed a significant benefit for the intensive protocol in reducing SSI. Beneficial effects in reducing SSI were confirmed in studies with very strict and moderately strict control, and the effect was similar in both groups (P = 0.328). 6 Although a higher risk of hypoglycemic events was observed with the intensive protocol, the protocol including a very strict control group did not increase the risk of postoperative death and stroke compared with the conventional protocol in surgical patients, 23 and it was concluded that an intensive protocol can be carried out safely without the risk of serious adverse events in surgical patients ( Table 2 ). The result of this meta-analysis, however, should be interpreted with caution. Most of the studies included were done in patients undergoing cardiac surgery or major gastrointestinal surgeries with a substantial proportion of the study population having a postoperative ICU stay. In the ICU, a high adherence rate to the insulin treatment regimen and BG measurement protocol is assured. It remains unknown whether the results can be extrapolated to a more general population.
In global guidelines for the prevention of SSI by the World Health Organization (WHO), 6 the panel suggested the use of perioperative intensive protocols for patients undergoing surgical procedures to reduce the risk of SSI. The CDC members of the WHO guidelines panel decided that the available evidence did not allow the definition of an optimal target BG, and emphasized that hypoglycemia associated with intensive protocols carries a serious risk of life-threatening complications. 6 By contrast, the guidelines by the American College of Surgeons (ACS) and Surgical Infection Society (SIS) 7 specified the optimal target BG, and recommended that perioperative glycemic control should be between 110 and 150 mg/dL (moderately strict control) except in cardiac surgery patients for whom the target is <180 mg/dL, because a target BG of <110 mg/dL has been linked to adverse outcomes and increased episodes of hypoglycemia and do not decrease SSI risk compared with moderately strict control.
| RELATIONSHIP BETWEEN PERIOPERATIVE BG AND SSI IN PATIENTS WHO UNDERGO GASTROEN TE ROLOGICAL SURGERY
We previously reported independent risk factors associated with SSI in patients who underwent gastroenterological surgery 31 BG >200 mg/dL, which has been traditionally defined as clinically significant hyperglycemia, was observed in 28.1% of patients. SSI occurred in 263 of 1555 patients (16.9%) and 119 of them had incisional SSI, whereas 180 had organ/space SSI (36 had both). Independent factors associated with BG >200 mg/dL are shown in Table 3 .
Among surgical procedures, hepatobiliary-pancreatic surgery and esophagectomy were independent risk factors for postoperative hyperglycemia.
T A B L E 2 Clinical outcomes of intensive insulin therapy and recommendation for glycemic control in patients undergoing surgery and in those who are critically ill Significant level of residuals: AE 1.96, P < 0.05; AE 2.58, P < 0.01. Systematic review and meta-analysis addressed a significant association between DM and SSI, 21 and hyperglycemia in DM patients who undergo surgery is associated with increased rates of SSI. Although non-DM patients had a lower incidence and decreased severity of hyperglycemia compared with DM patients, hyperglycemia was also associated with adverse outcomes in non-DM patients. 13, 16, 17 In the assessment of operative-day BG in non-DM patients who underwent colectomy, normoglycemia (≤120 mg/dL) endured in 26.2%, whereas 53.6% had BG of 121-160 mg/dL, 23 showed that the benefit of an intensive protocol over a conventional protocol in reducing SSI was consistent in patients both with and without DM. If the second theory is true, appropriate use of insulin for non-DM patients is a target for quality improvement. In fact, Kwon et al. 13 found that those with hyperglycemia on the day of surgery who received insulin had no significant increase in infection. Furthermore, among patients who had hyperglycemia and received insulin, those whose BG was corrected had significantly lower rates of adverse events than those who had persistent hyperglycemia in both DM and non-DM populations. 17 These findings strongly support the monitoring of BG level and early consideration of management strategies for glycemic control after surgery, even in non-DM patients. Guidelines by WHO 6 and ACS/ SIS 7 suggest an intensive protocol for both DM and non-DM adult patients undergoing surgical procedures to reduce the risk of SSI.
T A B L E 5 Multivariate analysis on the effect of each blood glucose concentration category on surgical site infections in patients with and without diabetes who underwent gastroenterological surgery
Subjects
Odds ratio for SSI in each blood glucose level category (95% CI, P-value) 
| INSULIN THERAPY IN PATIENTS WITH PERIOPERATIVE HYPERGLYCEMIA
When insulin was given to surgical patients with hyperglycemia, which was otherwise an independent factor for several adverse events including infections, the odds for infection were no longer significant. 10 Important processes of care for insulin therapy include use of a validated insulin titration program, frequent BG monitoring, and avoidance of finger-stick glucose testing through the use of arterial or venous glucose samples. 35 Table 7 shows the glucose management protocol by continuous insulin infusion to achieve the target BG of ≤150 mg/dL in surgical patients admitted to the ICU. 37 (Table 7) .
Recently, a computer-based insulin infusion protocol has been introduced in the ICU setting, for which improved glycemic control over the manual protocol was reported. 38 Saur et al. 39 described that surgical ICU patients who were managed using a software-guided program achieved tighter glycemic control and fewer glycemic derangements than those managed with the paper-based insulin dosing regimen. In computer-based systems, the initiation screen requires entry of the current BG as well as target high and low BG limits. After verifying protocol parameters the physician clicks 'calculate drip rate' and the insulin drip rate is printed on the screen. With subsequent bedside BG testing, nurses enter protocol-mandated glucose reading into the system's 'titration screen', and adjust the insulin drip rates based on the recommendations provided. 38 
| CONCLUSION S
A target BG of ≤150 mg/dL is recommended in non-DM patients who undergo gastroenterological surgery. Additional study is required to determine an optimal target BG for surgical DM patients. In contrast, a target BG level of 140-180 mg/dL is recommended in critically ill patients such as those with postoperative complications including infections. Because of the risk of hypoglycemia, a conventional protocol is indicated for patients admitted to the general ward where frequent glucose measurement is not assured. To achieve the target BG and minimize the risk of hypoglycemia in the intensive protocol, it is necessary to improve current practice in surgical patients by ensuring the T A B L E 7 Glucose management protocol to achieve target glucose level of ≤150 mg/dL in surgical patients admitted to the ICU appropriate insulin delivery and management protocol according to the best available evidence. Further RCT comparing moderately strict control and very strict control are needed to clarify the optimal intensive protocol that reveals a beneficial effect in reducing SSI without a significantly increased risk of hypoglycemia.
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